Pharma BD Deal Intelligence
A related-party deal that torched $1.4B of market cap on announcement, then quietly folded the acquired asset into a spin-off before the parent went private — no durable value creation ever demonstrated publicly.
Full analysis, sources & comparables →FiercePharma framed the deal as related-party concern: Bever was controlled by Bristley Enterprises (owned by non-exec director Dr. Alexander Shuster), who…
Pharmstandard frames the Bever purchase around guaranteeing API supply and a planned OTC unit spin-off, reporting the company's strategic rationale to secure…
Pharmstandard closed the Bever acquisition August 2013, citing strategic rationale of long-term fixed-cost API supply for Arbidol and Aphobazolum and…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Pharmstandard acquired Singapore-based Bever Pharmaceutical for $590M ($542M equity + $48M cash) to secure long-term API supply for Arbidol and Aphobazolum OTC franchises.
A related-party deal that torched $1.4B of market cap on announcement, then quietly folded the acquired asset into a spin-off before the parent went private — no durable value creation ever demonstrated publicly.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pharmstandard OJSC / Bever Pharmaceutical Pte Ltd (this deal) | 2013 | $590M | 41 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| bioMerieux SA / BioFire Diagnostics Inc. | 2013 | $485M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2013 deals · Infectious Disease deals